drugset / Trial / NCT07204457
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
RandomizedParallel-groupDouble-blindPrevention
Summary
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Timeline
- Start
- 2025-10-15
- Primary completion
- 2026-09
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EG-MCV4 | Vaccine | 0.25 ml | Intramuscular |
| Subject | EG-MCV4 | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Menveo | Vaccine | 0.5 ml | Intramuscular |